{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:08Z","timestamp":1792788008529,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81988101"],"award-info":[{"award-number":["81988101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of China","award":["2021YFC2501001"],"award-info":[{"award-number":["2021YFC2501001"]}]},{"name":"Beijing Hospitals Authority Youth Programme","award":["QML20231116"],"award-info":[{"award-number":["QML20231116"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06178-y","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T07:00:32Z","timestamp":1739862032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Integrative analysis of T cell-mediated tumor killing-related genes reveals KIF11 as a novel therapeutic target in esophageal squamous cell carcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Xinxin","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangwang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjie","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingnan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7646-4795","authenticated-orcid":false,"given":"Qimin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"6178_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"6178_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115\u201332.","journal-title":"CA Cancer J Clin"},{"key":"6178_CR3","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","volume":"6","author":"H Zeng","year":"2018","unstructured":"Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H. Changing cancer survival in China during 2003\u201315: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6:e555\u201367.","journal-title":"Lancet Glob Health"},{"key":"6178_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature13176","volume":"509","author":"Y Song","year":"2014","unstructured":"Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91\u20135.","journal-title":"Nature"},{"key":"6178_CR5","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1200\/JCO.22.01490","volume":"41","author":"H-X Wu","year":"2023","unstructured":"Wu H-X, Pan Y-Q, He Y, Wang Z-X, Guan W-L, Chen Y-X, Yao Y-C, Shao N-Y, Xu R-H, Wang F. Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1\u2013expressing esophageal squamous cell carcinoma: a post hoc analysis of JUPITER-06 and meta-analysis. J Clin Oncol. 2023;41:1735\u201346.","journal-title":"J Clin Oncol"},{"key":"6178_CR6","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651\u201368.","journal-title":"Nat Rev Immunol"},{"key":"6178_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MW, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"6178_CR8","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550\u20138.","journal-title":"Nat Med"},{"key":"6178_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22:209\u201323.","journal-title":"Nat Rev Immunol"},{"key":"6178_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560:382\u20136.","journal-title":"Nature"},{"key":"6178_CR11","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu C-H, Doi T, Moriwaki T, Kim S-B, Lee S-H. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38:4138\u201348.","journal-title":"J Clin Oncol"},{"key":"6178_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375\u201384.","journal-title":"Lancet Oncol"},{"key":"6178_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","volume":"541","author":"CGAR Network","year":"2017","unstructured":"Network CGAR. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541:169.","journal-title":"Nature"},{"key":"6178_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299\u2013309.","journal-title":"Nature"},{"key":"6178_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52:17\u201335.","journal-title":"Immunity"},{"key":"6178_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.09.010","author":"C Galassi","year":"2024","unstructured":"Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024. https:\/\/doi.org\/10.1016\/j.ccell.2024.09.010.","journal-title":"Cancer Cell"},{"key":"6178_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","volume":"20","author":"RD Leone","year":"2020","unstructured":"Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20:516\u201331.","journal-title":"Nat Rev Cancer"},{"key":"6178_CR18","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy. Science. 2018;362:eaar3593.","journal-title":"Science"},{"key":"6178_CR19","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41422-020-0333-6","volume":"30","author":"Y Cui","year":"2020","unstructured":"Cui Y, Chen H, Xi R, Cui H, Zhao Y, Xu E, Yan T, Lu X, Huang F, Kong P. Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma. Cell Res. 2020;30:902\u201313.","journal-title":"Cell Res"},{"key":"6178_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12967-022-03252-7","volume":"20","author":"X Zhang","year":"2022","unstructured":"Zhang X, Gari A, Li M, Chen J, Qu C, Zhang L, Chen J. Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti-PD-1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma. J Transl Med. 2022;20:61.","journal-title":"J Transl Med"},{"key":"6178_CR21","doi-asserted-by":"publisher","first-page":"6268","DOI":"10.1038\/s41467-020-20019-0","volume":"11","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Chen Z, Han Y, Han L, Zou X, Zhou B, Hu R, Hao J, Bai S, Xiao H, et al. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nat Commun. 2020;11:6268.","journal-title":"Nat Commun"},{"key":"6178_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1356147","volume":"6","author":"Y Li","year":"2017","unstructured":"Li Y, Lu Z, Che Y, Wang J, Sun S, Huang J, Mao S, Lei Y, Chen Z, He J. Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma. Oncoimmunology. 2017;6: e1356147.","journal-title":"Oncoimmunology"},{"key":"6178_CR23","doi-asserted-by":"crossref","unstructured":"Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, Tsoucas D, Qiu X, Lim K, Rao P, et al: A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 2018, 359:770\u2013775.","DOI":"10.1126\/science.aao1710"},{"key":"6178_CR24","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","volume":"35","author":"B Ru","year":"2019","unstructured":"Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I. TISIDB: an integrated repository portal for tumor\u2013immune system interactions. Bioinformatics. 2019;35:4200\u20132.","journal-title":"Bioinformatics"},{"key":"6178_CR25","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nrm2774","volume":"10","author":"N Hirokawa","year":"2009","unstructured":"Hirokawa N, Noda Y, Tanaka Y, Niwa S. Kinesin superfamily motor proteins and intracellular transport. Nat Rev Mol Cell Biol. 2009;10:682\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6178_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/humupd\/dmx010","volume":"23","author":"NJ Camlin","year":"2017","unstructured":"Camlin NJ, McLaughlin EA, Holt JE. Motoring through: the role of kinesin superfamily proteins in female meiosis. Hum Reprod Update. 2017;23:409\u201320.","journal-title":"Hum Reprod Update"},{"key":"6178_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.tcb.2018.08.004","volume":"29","author":"BJ Mann","year":"2019","unstructured":"Mann BJ, Wadsworth P. Kinesin-5 regulation and function in mitosis. Trends Cell Biol. 2019;29:66\u201379.","journal-title":"Trends Cell Biol"},{"key":"6178_CR28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/biom14040386","volume":"14","author":"W Gao","year":"2024","unstructured":"Gao W, Lu J, Yang Z, Li E, Cao Y, Xie L. Mitotic functions and characters of KIF11 in cancers. Biomolecules. 2024;14:386.","journal-title":"Biomolecules"},{"key":"6178_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nature03503","volume":"435","author":"LC Kapitein","year":"2005","unstructured":"Kapitein LC, Peterman EJ, Kwok BH, Kim JH, Kapoor TM, Schmidt CF. The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature. 2005;435:114\u20138.","journal-title":"Nature"},{"key":"6178_CR30","doi-asserted-by":"crossref","unstructured":"Venere M, Horbinski C, Crish JF, Jin X, Vasanji A, Major J, Burrows AC, Chang C, Prokop J, Wu Q: The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. Sci Transl Med 2015, 7:304ra143\u2013304ra143..","DOI":"10.1126\/scitranslmed.aac6762"},{"key":"6178_CR31","doi-asserted-by":"publisher","first-page":"514","DOI":"10.7150\/ijbs.54074","volume":"17","author":"D Wei","year":"2021","unstructured":"Wei D, Rui B, Qingquan F, Chen C, Ping HY, Xiaoling S, Hao W, Jun G. KIF11 promotes cell proliferation via ERBB2\/PI3K\/AKT signaling pathway in gallbladder cancer. Int J Biol Sci. 2021;17:514\u201326.","journal-title":"Int J Biol Sci"},{"key":"6178_CR32","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41419-023-06313-x","volume":"14","author":"S Shi","year":"2023","unstructured":"Shi S, Guo D, Ye L, Li T, Fei Q, Lin M, Yu X, Jin K, Wu W. Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer. Cell Death Dis. 2023;14:778.","journal-title":"Cell Death Dis"},{"key":"6178_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139808","volume":"10","author":"G Sawada","year":"2015","unstructured":"Sawada G, Niida A, Hirata H, Komatsu H, Uchi R, Shimamura T, Takahashi Y, Kurashige J, Matsumura T, Ueo H. An integrative analysis to identify driver genes in esophageal squamous cell carcinoma. PLoS ONE. 2015;10: e0139808.","journal-title":"PLoS ONE"},{"key":"6178_CR34","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1136\/gutjnl-2013-305806","volume":"63","author":"J Li","year":"2014","unstructured":"Li J, Chen Z, Tian L, Zhou C, He MY, Gao Y, Wang S, Zhou F, Shi S, Feng X. LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut. 2014;63:1700\u201310.","journal-title":"Gut"},{"key":"6178_CR35","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47\u2013e47.","journal-title":"Nucleic Acids Res"},{"key":"6178_CR36","doi-asserted-by":"crossref","unstructured":"Villanueva RAM, Chen ZJ: ggplot2: elegant graphics for data analysis. Taylor & Francis; 2019.","DOI":"10.1080\/15366367.2019.1565254"},{"key":"6178_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137.","journal-title":"OMICS"},{"key":"6178_CR38","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","volume":"16","author":"R Tibshirani","year":"1997","unstructured":"Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16:385\u201395.","journal-title":"Stat Med"},{"key":"6178_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"JH Friedman","year":"2010","unstructured":"Friedman JH, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1\u201322.","journal-title":"J Stat Softw"},{"key":"6178_CR40","unstructured":"Hothorn T: maxstat: Maximally Selected Rank Statistics. R package version 0.7\u201325. R Project; 2017."},{"key":"6178_CR41","doi-asserted-by":"crossref","unstructured":"Kassambara A, Kosinski M, Biecek P: survminer: Drawing Survival Curves using'ggplot2'. CRAN: Contributed Packages 2016.","DOI":"10.32614\/CRAN.package.survminer"},{"key":"6178_CR42","unstructured":"Therneau T: A package for survival analysis in S. version 2.38. 2015."},{"key":"6178_CR43","first-page":"1","volume":"5","author":"FE Harrell Jr","year":"2016","unstructured":"Harrell FE Jr. rms: Regression modeling strategies. R Pack Vers. 2016;5:1\u2013263.","journal-title":"R Pack Vers"},{"key":"6178_CR44","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel Iii EE, Koeppen H, Astarita JL, Cubas R. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138.","journal-title":"Nature"},{"issue":"934\u2013949","key":"6178_CR45","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Mart\u00edn-Algarra S, Mandal R, Sharfman WH. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171(934\u2013949): e916.","journal-title":"Cell"},{"key":"6178_CR46","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","volume":"10","author":"H Jung","year":"2019","unstructured":"Jung H, Kim HS, Kim JY, Sun J-M, Ahn JS, Ahn M-J, Park K, Esteller M, Lee S-H, Choi JK. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun. 2019;10:4278.","journal-title":"Nat Commun"},{"key":"6178_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67\u201376.","journal-title":"Lancet"},{"key":"6178_CR48","doi-asserted-by":"publisher","first-page":"e26476","DOI":"10.7554\/eLife.26476","volume":"6","author":"J Racle","year":"2017","unstructured":"Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017;6:e26476.","journal-title":"Elife"},{"key":"6178_CR49","doi-asserted-by":"publisher","first-page":"514","DOI":"10.7150\/ijbs.54074","volume":"17","author":"D Wei","year":"2021","unstructured":"Wei D, Rui B, Qingquan F, Chen C, Xiaoling S, Hao W, Jun G. KIF11 promotes cell proliferation via ERBB2\/PI3K\/AKT signaling pathway in gallbladder cancer. Int J Biol Sci. 2021;17:514.","journal-title":"Int J Biol Sci"},{"key":"6178_CR50","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.4143\/crt.2018.460","volume":"51","author":"J Zhou","year":"2019","unstructured":"Zhou J, Chen W-R, Yang L-C, Wang J, Sun J-Y, Zhang W-W, He Z-Y, Wu S-G. KIF11 functions as an oncogene and is associated with poor outcomes from breast cancer. Cancer Res Treat. 2019;51:1207\u201321.","journal-title":"Cancer Res Treat"},{"key":"6178_CR51","doi-asserted-by":"publisher","first-page":"92106","DOI":"10.18632\/oncotarget.20785","volume":"8","author":"M Jiang","year":"2017","unstructured":"Jiang M, Zhuang H, Xia R, Gan L, Wu Y, Ma J, Sun Y, Zhuang Z. KIF11 is required for proliferation and self-renewal of docetaxel resistant triple negative breast cancer cells. Oncotarget. 2017;8:92106.","journal-title":"Oncotarget"},{"key":"6178_CR52","doi-asserted-by":"crossref","unstructured":"Venere M, Horbinski C, Crish JF, Jin X, Vasanji A, Major J, Burrows AC, Chang C, Prokop J, Wu Q: The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. Sci Transl Med 2015, 7:304ra143\u2013304ra143.","DOI":"10.1126\/scitranslmed.aac6762"},{"key":"6178_CR53","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"J-M Sun","year":"2021","unstructured":"Sun J-M, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges J-P, Li Z, Kim S-B. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759\u201371.","journal-title":"Lancet"},{"key":"6178_CR54","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021;27:1410\u20138.","journal-title":"Nat Med"},{"key":"6178_CR55","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(21)00378-2","volume":"7","author":"X Meng","year":"2022","unstructured":"Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, Yang X, Shi P, Yang J, Yin X, et al. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:245\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6178_CR56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41586-022-04632-1","volume":"605","author":"C Chou","year":"2022","unstructured":"Chou C, Zhang X, Krishna C, Nixon BG, Dadi S, Capistrano KJ, Kansler ER, Steele M, Han J, Shyu A, et al. Programme of self-reactive innate-like T cell-mediated cancer immunity. Nature. 2022;605:139\u201345.","journal-title":"Nature"},{"key":"6178_CR57","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41571-020-0333-y","volume":"17","author":"A Byrne","year":"2020","unstructured":"Byrne A, Savas P, Sant S, Li R, Virassamy B, Luen SJ, Beavis PA, Mackay LK, Neeson PJ, Loi S. Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nat Rev Clin Oncol. 2020;17:341\u20138.","journal-title":"Nat Rev Clin Oncol"},{"key":"6178_CR58","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20:218\u201332.","journal-title":"Nat Rev Cancer"},{"key":"6178_CR59","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-090222-110914","author":"A Baessler","year":"2024","unstructured":"Baessler A, Vignali DA. T cell exhaustion. Ann Rev Immunol. 2024. https:\/\/doi.org\/10.1146\/annurev-immunol-090222-110914.","journal-title":"Ann Rev Immunol"},{"key":"6178_CR60","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"6178_CR61","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06178-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06178-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06178-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T07:00:41Z","timestamp":1739862041000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06178-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6178"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06178-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}